Downregulating trolls using novel antisense oligonucleotides to overcome resistance to chemotherapy
AssigneeH. Lee Moffitt Cancer Center and Research Institute, Inc.
InventorsElsa FLORES, Marco NAPOLI
Life of this patent
Estimating the term…
Abstract
Disclosed herein are 2 novel long non-coding RNAs (lncRNAs). TROLL-2C and TROLL-3A. It is shown herein that lncRNAs TROLL-2C and TROLL-3A are suitable targets for cancer therapies and can be used to make prognostic determinations about a cancer and determine if immune checkpoint inhibitors should be used to treat a cancer.
Claims17
A method of treating a cancer in a subject comprising knocking down expression of TROLL-2C and/or TROLL-3A in the subject.
An antisense oligonucleotide comprising SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, or SEQ ID NO:
- 7.
A pharmaceutical composition comprising a therapeutically effective amount of one or more of an antisense oligonucleotide as set forth in SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, or SEQ ID NO:
- 7, or a combination thereof, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.